Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for DS-5565

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for DS-5565?

DS-5565 is an investigational drug.

There have been 12 clinical trials for DS-5565. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2014.

The most common disease conditions in clinical trials are Neuralgia, Diabetic Neuropathies, and Myofascial Pain Syndromes. The leading clinical trial sponsors are Daiichi Sankyo Inc., Daiichi Sankyo Co., Ltd., and INC Research.

There are seven US patents protecting this investigational drug and one hundred and twenty-three international patents.

Recent Clinical Trials for DS-5565
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic PainDaiichi Sankyo Co., Ltd.Phase 3
Study of Mirogabalin for Central Neuropathic PainDaiichi Sankyo Co., Ltd.Phase 3
DS-5565 Phase III Study for Renal Impairment in Japanese SubjectsCMIC Co, Ltd. JapanPhase 3

See all DS-5565 clinical trials

Clinical Trial Summary for DS-5565

Top disease conditions for DS-5565
Top clinical trial sponsors for DS-5565

See all DS-5565 clinical trials

US Patents for DS-5565

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
DS-5565   Start Trial Bicyclic .gamma.-amino acid derivative Daiichi Sankyo Company, Ltd. (Tokyo, JP)   Start Trial
DS-5565   Start Trial Method for producing bicyclic .gamma.-amino acid derivative Daiichi Sankyo Company, Limited (Tokyo, JP)   Start Trial
DS-5565   Start Trial Methods for producing bicyclic compounds via claisen rearrangements Daiichi Sankyo Company, Limited (Tokyo, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.